ClinicalTrials.gg

Program

GIPR Agonist LY3537021

In Eli Lilly’s pipeline, GIPR agonist. Its studies are mostly in Nausea · Diabetes Mellitus, Type 2, led by Eli Lilly.

Furthest: phase 2, since Sep 5, 20253 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly31 open or runningphase 2since Sep 5, 2025Oct 12, 2020Dec 2026phase 2 · NCT07169851
  • Named in Eli Lilly’s own pipeline as GIPR Agonist Long Acting, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 12, 2020First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT04586907 · 85 enrolled · Singapore
  2. Jun 30, 2022Phase 1 study in HealthyNCT05444569 · 47 enrolled · Singapore
  3. Sep 5, 2025Phase 2 study in NauseaNCT07169851 · 204 planned · United States, Australia, China and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in NauseaNCT07169851

TargetBeta

“GIPR agonist”the company's pipeline, read by Claude · source
“A long-acting glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, with potential weight-reducing, anti-diabetic, anti-nauseant and anti-emetic activities. Upon subcutaneous administration, GIPR agonist LY3537021 targets, binds to and activates GIPR. This may moderate nausea and …”NCIt, read by Claude
“A long-acting glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, ”NCIt, by rule

Other programs on GIPR

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
brenipatideEli Lillyphase 319
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
macupatideEli Lillyphase 28
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07169851Nausea · United States, Australia, China and more2RecruitingDec 2026204
NCT05444569Healthy · Singapore1CompletedFeb 24, 202347
NCT04586907Diabetes Mellitus, Type 2 · Singapore1CompletedNov 30, 202185

How it is read

Names in the registry

  • “LY3537021”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.